These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Eye color as a risk factor for acquired sensorineural hearing loss: a review. Mujica-Mota MA; Schermbrucker J; Daniel SJ Hear Res; 2015 Feb; 320():1-10. PubMed ID: 25529530 [TBL] [Abstract][Full Text] [Related]
4. [Kanamycin ototoxicity and melanin in the inner ear]. Du XP Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(1):14-6, 58. PubMed ID: 8352991 [TBL] [Abstract][Full Text] [Related]
5. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected. Schmidt CM; Knief A; Lagosch AK; Deuster D; am Zehnhoff-Dinnesen A Ear Hear; 2008 Dec; 29(6):830-7. PubMed ID: 18772725 [TBL] [Abstract][Full Text] [Related]
6. Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents. Gersten BK; Fitzgerald TS; Fernandez KA; Cunningham LL J Assoc Res Otolaryngol; 2020 Aug; 21(4):303-321. PubMed ID: 32583132 [TBL] [Abstract][Full Text] [Related]
7. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss. Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950 [TBL] [Abstract][Full Text] [Related]
9. Progressive bilateral sensorineural hearing loss probably induced by chronic cyclosporin A treatment after renal transplantation for focal glomerulosclerosis. Marioni G; Perin N; Tregnaghi A; Bellemo B; Staffieri A; de Filippis C Acta Otolaryngol; 2004 Jun; 124(5):603-7. PubMed ID: 15267179 [TBL] [Abstract][Full Text] [Related]
10. [Clinical study of the ototoxicity of cisplatin]. Basterra J; Iranzo C; Marco J An Otorrinolaringol Ibero Am; 1985; 12(2):167-72. PubMed ID: 4039901 [No Abstract] [Full Text] [Related]
11. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Schweitzer VG Laryngoscope; 1993 Apr; 103(4 Pt 2):1-52. PubMed ID: 8464301 [TBL] [Abstract][Full Text] [Related]
16. Factors influencing ototoxicity in ovarian cancer patients treated with Cis-platinum based chemotherapy. Hallmark RJ; Snyder JM; Jusenius K; Tamimi HK Eur J Gynaecol Oncol; 1992; 13(1):35-44. PubMed ID: 1547792 [TBL] [Abstract][Full Text] [Related]
17. [Cisplatin-induced hearing loss in children in relation to eye color]. Martin HC; Schmidt CM; Boos HJ; Heinecke A; Dinnesen AG HNO; 2007 Jun; 55(6):489-96. PubMed ID: 17180696 [TBL] [Abstract][Full Text] [Related]
18. [Changes in transitory evoked otoacoustic emissions in chemotherapy with cisplatin and 5FU]. Beck A; Maurer J; Welkoborsky HJ; Mann W HNO; 1992 Apr; 40(4):123-7. PubMed ID: 1601678 [TBL] [Abstract][Full Text] [Related]
19. Cisplatin in children: hearing loss correlates with iris and skin pigmentation. Todd NW; Alvarado CS; Brewer DB J Laryngol Otol; 1995 Oct; 109(10):926-9. PubMed ID: 7499942 [TBL] [Abstract][Full Text] [Related]
20. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. Knight KR; Kraemer DF; Winter C; Neuwelt EA J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]